Edition:
United States

Medicines Co (MDCO.O)

MDCO.O on Nasdaq

33.13USD
23 Oct 2017
Change (% chg)

$-0.85 (-2.50%)
Prev Close
$33.98
Open
$34.17
Day's High
$34.17
Day's Low
$33.05
Volume
788,287
Avg. Vol
1,146,076
52-wk High
$55.95
52-wk Low
$30.80

Latest Key Developments (Source: Significant Developments)

The Medicines Company announces FDA approval of Vabomere
Wednesday, 30 Aug 2017 07:00am EDT 

Aug 30 (Reuters) - Medicines Co :The Medicines Company announces FDA approval of Vabomere (meropenem and vaborbactam).Vabomere expected to be available in Q4 of 2017.  Full Article

Alnylam says ‍inclisiran phase III development program gearing up​
Monday, 28 Aug 2017 07:00am EDT 

Aug 28 (Reuters) - Alnylam Pharmaceuticals Inc :New, one-year data from orion-1 phase ii study of inclisiran extends excellent long-term efficacy and safety profile, affirming dose for phase iii trials.Alnylam pharmaceuticals inc - ‍inclisiran phase iii development program gearing up​.  Full Article

Medicines Co reports Q2 GAAP loss per share $5.52 from continuing operations
Wednesday, 9 Aug 2017 07:00am EDT 

Aug 9 (Reuters) - Medicines Co :The Medicines Company reports second quarter 2017 business and financial results.Q2 GAAP loss per share $5.52 from continuing operations.Q2 revenue $18.7 million versus $54.7 million.Q2 earnings per share view $-1.96 -- Thomson Reuters I/B/E/S.Q2 revenue view $28.4 million -- Thomson Reuters I/B/E/S.Q2 adjusted non-GAAP loss per share $1.02 from continuing operations.  Full Article

The Medicines Company announces TANGO-2 trial of meropenem-vaborbactam stopped early for superior benefit-risk compared to best available therapy for CRE
Tuesday, 25 Jul 2017 07:00am EDT 

July 25 (Reuters) - Medicines Co :The Medicines Company announces TANGO-2 trial of meropenem-vaborbactam (formerly, carbavance) stopped early for superior benefit-risk compared to best available therapy for CRE.Medicines Co - ‍company also announces vabomere (TM) as U.S. and European trade name for meropenem-vaborbactam​.Medicines Co - ‍trial stopped early following recommendation by independent data safety and monitoring board​.Medicines Co - will continue to enroll patients into an amended, single-arm study protocol for treatment with meropenem-vaborbactam at selected sites​.Medicines Co - ‍DSMB's recommendation to discontinue randomization into TANGO-2 trial was based on results of an interim analysis of data from TANGO-2​.Medicines Co - expects that data from TANGO-2 trial will be presented at a future medical conference and published in a peer-reviewed journal​.​.  Full Article

Medicines Co says commenced implementation of workforce reduction​
Friday, 2 Jun 2017 04:58pm EDT 

June 2 (Reuters) - Medicines Co ::Medicines Co - ‍on june 1, 2017, Medicines company commenced implementation of a workforce reduction​.Medicines - ‍workforce reduction will result in company reducing its personnel by approximately 60 employees​.Medicines - ‍workforce reduction representing approximately 15 pct of company's workforce - sec filing​.Medicines-‍expects to record pre-tax charge of about $270 million to $280 million associated with discontinuation and market withdrawal of Ionsys in U.S..Medicines - ‍company expects charges will be recognized in Q2 of 2017​.Medicines- expects to realize estimated annualized cost savings from voluntary discontinuation and market withdrawal of ionsys of approximately $35 million​.Medicines Co - ‍voluntary discontinuation and withdrawal from market of Ionsys is not due to any safety or product quality concerns​.Medicines-‍workforce reduction was in connection with discontinuation & market withdrawal of Ionsys in U.S., cessation of commercialization activities​.  Full Article

Medicines says U.S. District court issued order preliminarily approving proposed settlement by co, plaintiffs in case related to co's clinical trial of Cangrelor
Friday, 19 May 2017 05:09pm EDT 

May 19 (Reuters) - Medicines Co :Medicines-U.S. District court issued order preliminarily approving proposed settlement by co, plaintiffs in case related to co's clinical trial of Cangrelor.Medicines Co - Proposed settlement requires company to implement certain corporate governance measures - SEC Filing.Medicines Co - Proposed settlement requires co to pay certain attorneys' fees, expenses to plaintiff's counsel in an amount to be determined by court.  Full Article

The Medicines Company Q1 loss per share $1.44
Wednesday, 26 Apr 2017 07:15am EDT 

April 26 (Reuters) - Medicines Co :The Medicines Company reports first-quarter 2017 financial results.Q1 loss per share $1.44 from continuing operations.Q1 revenue $24.2 million versus $50.3 million.Q1 revenue view $31.2 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-1.30 -- Thomson Reuters I/B/E/S.Q1 adjusted loss per share $1.05 from continuing operations.Medicines Co - at March 31, 2017, company had $436.7 million in cash and cash equivalents compared to $541.8 million at end of 2016.Medicines Co - at March 31, 2017, company had $436.7 million in cash and cash equivalents compared to $541.8 million at end of 2016.  Full Article

Medicines Co, Alnylam Pharma announce agreement with FDA on phase III clinical program for inclisiran
Wednesday, 26 Apr 2017 07:00am EDT 

April 26 (Reuters) - Medicines Co :The medicines company and alnylam pharmaceuticals announce agreement with fda on phase iii clinical program for inclisiran.Medicines co- nda submission anticipated at or around end of 2019.Medicines co- company has received final, end-of-phase ii meeting minutes from fda.  Full Article

Medicines Co reports Q4 loss per share $1.77 from continuing operations
Tuesday, 28 Feb 2017 07:00am EST 

Medicines Co : The Medicines Company reports fourth-quarter and full-year 2016 financial results . Q4 loss per share $1.77 from continuing operations . Q4 revenue $25.2 million versus I/B/E/S view $26.9 million . Q4 earnings per share view $-1.43 -- Thomson Reuters I/B/E/S .Q4 adjusted loss per share $1.19 from continuing operations.  Full Article

Medicines Co says FDA accepts NDA filing for intravenous antibiotic carbavance
Tuesday, 21 Feb 2017 07:15am EST 

Medicines Co : The Medicines Company announces FDA filing acceptance of new drug application for intravenous antibiotic carbavance(meropenem-vaborbactam) . Medicines Co - FDA does not currently plan to hold an advisory committee meeting to discuss application .Medicines co says tango 2 trial is ongoing and company expects results to be available before end of Q3 of 2017.  Full Article

Alnylam's RNAi drug succeeds in key study, shares soar

Alnylam Pharmaceuticals Inc's RNAi-based drug that targets a rare genetic disease met the main goal of a key study, in a breakthrough for the new class of medicines that works by blocking disease-causing proteins.